HSDT
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Solana Company (HSDT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Growth (A-); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | B (3.2) | A- (3.9) | D+ (1.7) | C+ (2.7) | C+ (2.5) | C+ (2.8) |
| 2026-11-05 | B (3.2) | A- (3.9) | D+ (1.7) | B (3.2) | C+ (2.6) | B- (2.9) |
| 2026-10-29 | B- (3.1) | A- (3.9) | D+ (1.7) | B (3.3) | C+ (2.5) | B- (2.9) |
| 2026-10-22 | B- (3.1) | A- (3.9) | D+ (1.7) | B (3.4) | C+ (2.5) | B- (2.9) |
| 2026-10-15 | B- (3.1) | A- (3.9) | D+ (1.7) | B- (3.0) | C+ (2.5) | C+ (2.8) |